Overview
Double uterus-hemivagina-renal agenesis syndrome, also known as Herlyn-Werner-Wunderlich (HWW) syndrome or obstructed hemivagina and ipsilateral renal anomaly (OHVIRA), is a rare congenital malformation involving the Müllerian (paramesonephric) and Wolffian (mesonephric) duct systems. It is characterized by a triad of findings: uterus didelphys (double uterus), obstructed hemivagina (typically caused by a longitudinal vaginal septum), and ipsilateral renal agenesis (absence of one kidney on the same side as the vaginal obstruction). These three features arise from a developmental defect during embryogenesis affecting the coordinated development of the reproductive and urinary tracts. The condition predominantly affects females and is often diagnosed around the time of puberty (menarche), when menstrual blood accumulates behind the obstructed hemivagina, forming a hematocolpos. Patients typically present with progressive pelvic pain, a pelvic mass, dysmenorrhea, or abnormal vaginal discharge that may become foul-smelling if secondary infection occurs. Some patients may also develop hematometra (blood accumulation in the uterus) or endometriosis due to retrograde menstruation. Renal agenesis is usually asymptomatic and may be discovered incidentally during imaging for the gynecological symptoms. Diagnosis is established through imaging modalities such as pelvic ultrasound, MRI, and sometimes hysteroscopy or laparoscopy. Treatment is primarily surgical and involves excision or marsupialization of the obstructing vaginal septum to allow drainage of the obstructed hemivagina. This procedure is generally curative for the obstructive symptoms and has excellent outcomes. Following appropriate surgical management, most patients retain normal menstrual function and have favorable reproductive potential, although they may face a higher risk of obstetric complications related to the uterine anomaly. Long-term follow-up is recommended to monitor for potential complications including endometriosis and to provide appropriate obstetric counseling.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Juvenile
Begins in the teen years
Treatments
No FDA-approved treatments are currently listed for Double uterus-hemivagina-renal agenesis syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Double uterus-hemivagina-renal agenesis syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Double uterus-hemivagina-renal agenesis syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Double uterus-hemivagina-renal agenesis syndrome.
Community
No community posts yet. Be the first to share your experience with Double uterus-hemivagina-renal agenesis syndrome.
Start the conversation →Latest news about Double uterus-hemivagina-renal agenesis syndrome
No recent news articles for Double uterus-hemivagina-renal agenesis syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Double uterus-hemivagina-renal agenesis syndrome
What is Double uterus-hemivagina-renal agenesis syndrome?
Double uterus-hemivagina-renal agenesis syndrome, also known as Herlyn-Werner-Wunderlich (HWW) syndrome or obstructed hemivagina and ipsilateral renal anomaly (OHVIRA), is a rare congenital malformation involving the Müllerian (paramesonephric) and Wolffian (mesonephric) duct systems. It is characterized by a triad of findings: uterus didelphys (double uterus), obstructed hemivagina (typically caused by a longitudinal vaginal septum), and ipsilateral renal agenesis (absence of one kidney on the same side as the vaginal obstruction). These three features arise from a developmental defect during
How is Double uterus-hemivagina-renal agenesis syndrome inherited?
Double uterus-hemivagina-renal agenesis syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Double uterus-hemivagina-renal agenesis syndrome typically begin?
Typical onset of Double uterus-hemivagina-renal agenesis syndrome is juvenile. Age of onset can vary across affected individuals.